newsfilter
← Latest News
GlobeNewswire·

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

ARGX
  • ADAPT OCULUS is the first study to show VYVGART significantly improves symptoms in ocular myasthenia gravis (oMG), meeting its primary endpoint with p=0.012 for ocular scores at Week 4.
  • ADAPT SERON data demonstrates VYVGART efficacy across MuSK+, LRP4+, & triple seronegative generalized myasthenia gravis (gMG) populations, supporting a priority review sBLA submission with a target FDA action date of May 10, 2026.
  • ADAPT Jr results indicate adolescent patients (ages 12-17) achieved minimal symptom expression in 72.7% of cycle one & 80% of cycle two.
  • ADHERE post hoc analysis supports early use of VYVGART Hytrulo in treatment-naïve CIDP patients, with 87.5% achieving early clinical improvement & a median response time of 39.5 days.
  • Real-world data shows 85.7% of patients successfully switched from IVIg to VYVGART Hytrulo due to efficacy, safety, or practical considerations.
  • argenx presented data on adimanebart in DOK7 congenital myasthenic syndromes (CMS), showing maintained improvements in QMG components & six-minute walk test performance during 30-week follow-up.
  • Phase 3 trial designs for empasiprubart in CIDP were presented for EMVIGORATE (head-to-head vs IVIg) & EMNERGIZE (vs placebo).
  • VYVGART Hytrulo is currently approved for gMG & CIDP, while VYVGART is approved for gMG & ITP (Japan only).
  • Safety profiles for both VYVGART & VYVGART Hytrulo highlight risks including infection, allergic reactions, & infusion/injection-related reactions, with common side effects being respiratory tract infections, headache, & urinary tract infections.
  • argenx plans to submit an sBLA to the FDA to expand VYVGART labeling to include oMG based on ADAPT OCULUS results.